989 related articles for article (PubMed ID: 32562159)
1. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
Vahedi E; Ghanei M; Ghazvini A; Azadi H; Izadi M; Panahi Y; Fathi S; Salesi M; Saadat SH; Ghazale AH; Rezapour M; Mozafari A; Zand N; Parsaei MR; Ranjkesh MH; Jafari R; Movaseghi F; Darabi E
Daru; 2020 Dec; 28(2):507-516. PubMed ID: 32562159
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
3. Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
Baralić K; Jorgovanović D; Živančević K; Antonijević Miljaković E; Antonijević B; Buha Djordjevic A; Ćurčić M; Đukić-Ćosić D
Toxicol Appl Pharmacol; 2020 Nov; 406():115237. PubMed ID: 32920000
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial.
Ghanei M; Solaymani-Dodaran M; Qazvini A; Ghazale AH; Setarehdan SA; Saadat SH; Ghobadi H; Hoseininia S; Elahikhah M; Samadi AH; Imani Y; Vahedi E; Babamahmoodi F; Rostami FT; Ardebili MHA; Ansarifar A; Golmaei FF; Asadollah A
Respir Res; 2021 Sep; 22(1):245. PubMed ID: 34526033
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
6. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Kalantari S; Fard SR; Maleki D; Taher MT; Yassin Z; Alimohamadi Y; Minaeian S
J Med Virol; 2021 Dec; 93(12):6557-6565. PubMed ID: 34255369
[TBL] [Abstract][Full Text] [Related]
7. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.
Sekhavati E; Jafari F; SeyedAlinaghi S; Jamalimoghadamsiahkali S; Sadr S; Tabarestani M; Pirhayati M; Zendehdel A; Manafi N; Hajiabdolbaghi M; Ahmadinejad Z; Kouchak HE; Jafari S; Khalili H; Salehi M; Seifi A; Golestan FS; Ghiasvand F
Int J Antimicrob Agents; 2020 Oct; 56(4):106143. PubMed ID: 32853672
[TBL] [Abstract][Full Text] [Related]
10. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
[TBL] [Abstract][Full Text] [Related]
11. Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
Rahmani H; Davoudi-Monfared E; Nourian A; Nabiee M; Sadeghi S; Khalili H; Abbasian L; Ghiasvand F; Seifi A; Hasannezhad M; Ghaderkhani S; Mohammadi M; Yekaninejad MS
Daru; 2020 Dec; 28(2):625-634. PubMed ID: 32857301
[TBL] [Abstract][Full Text] [Related]
12. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
[TBL] [Abstract][Full Text] [Related]
13. Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.
Dalili N; Kashefizadeh A; Nafar M; Poorrezagholi F; Firouzan A; Samadian F; Samavat S; Ziaie S; Fatemizadeh S
Trials; 2020 Jun; 21(1):489. PubMed ID: 32503620
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
15. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical Investigation.
Desai A; Santonocito OG; Caltagirone G; Kogan M; Ghetti F; Donadoni I; Porro F; Savevski V; Poretti D; Ciccarelli M; Martinelli Boneschi F; Voza A
Medicina (Kaunas); 2020 Oct; 56(11):. PubMed ID: 33138045
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J
Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712
[TBL] [Abstract][Full Text] [Related]
18. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
Reis G; Moreira Silva EADS; Medeiros Silva DC; Thabane L; Singh G; Park JJH; Forrest JI; Harari O; Quirino Dos Santos CV; Guimarães de Almeida APF; Figueiredo Neto AD; Savassi LCM; Milagres AC; Teixeira MM; Simplicio MIC; Ribeiro LB; Oliveira R; Mills EJ;
JAMA Netw Open; 2021 Apr; 4(4):e216468. PubMed ID: 33885775
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
[TBL] [Abstract][Full Text] [Related]
20. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
